Thus, a study by Baselga et al. demonstrated that everolimus, an mTOR inhibitor, combined with an aromatase inhibitor (AI) significantly improved progression-free survival (PFS) in patients with HR positive advanced breast cancer previously treated with AI [26]. The gene discussed is CYP19A1; the disease is breast cancer.